SCHEMBL1199230

SCHEMBL1199230

COc1ccccc1-c1csc(-n2ncc(C(=O)O)c2C(F)(F)F)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.69
MEN1 O00255 7/20 0.69
RAB9A P51151 5/20 0.69
NPC1 O15118 4/20 0.69
ATM Q13315 1/20 0.69
KDM4E B2RXH2 7/20 0.65
ALDH1A1 P00352 4/20 0.62
HPGD P15428 5/20 0.61
L3MBTL1 Q9Y468 4/20 0.61
POLB P06746 2/20 0.61
MAPT P10636 3/20 0.59
GAA P10253 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
CRHBP P24387 1/20 0.58
MC4R P32245 1/20 0.58
CRHR2 Q13324 1/20 0.58
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198475 0.88 KDM4E (0.80) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1197452 0.87 KDM4E (0.61) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL28787279 0.86 KDM4E (0.68) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL4830683 0.85 KDM4E (0.67) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL12875552 0.85 KMT2A (0.56) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1198188 0.84 KDM4E (0.58) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1198638 0.83 KDM4E (0.83) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1783253 0.81 KDM4E (0.59) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1198464 0.80 MEN1 (0.79) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL1198401 0.79 KDM4E (1.00) KMT2AMEN1RAB9ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
CN-102056907-A Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-05-11 CN disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KMT2A 3197/4885MEN1 2661/4885RAB9A 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.